Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma.
Nicole Basset‐Séguin(Université Paris Cité), Fred de Sauvage, S. Monestier(Hôpital de la Timone), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Florent Grange(Hôpital Lyon Sud), Hayley J. Sharpe(Babraham Institute), B. Guillot(Université de Montpellier), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), M. Bagot(Inserm), Laurent Mortier, Nicolas Poulalhon(Hospices Civils de Lyon), Caroline Robert(Institut Gustave Roussy), Amir Khammari(Inserm), Jeannie Hou, Brigitte Dréno(Nantes Université)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k